Determination of the value of glycated hemoglobin HbA1c and fructosamine in assessing the risk of perioperative complications after cardiac surgery in patients with type 2 diabetes.

INTRODUCTION: Patients with diabetes have a worse postoperative course and longer length of hospital stay after surgery. A good indicator of proper long-term (3 months) glycemic control is glycated hemoglobin (HbA1c), and fructosamine in the short term (2-3 weeks). AIM: To determine the degree of glycemic control evaluated preoperatively by HbA1c and/or fructosamine influence on the postoperative course of patients with diabetes undergoing coronary artery bypass grafting (CABG) in 2014-2015. MATERIAL AND METHODS: Before the operation HbA1c (N < 7.0) and fructosamine (N < 280 µmol/l) were measured and depending on the results the respondents were divided into 4 groups: group I (n = 46) - normal both parameters; group II (n = 22) - high both values; group III (n = 4) - normal fructosamine/HbA1c high; group IV (n = 33) - high HbA1c/fructosamine normal. Statistical analysis was performed using the t-test assuming p < 0.05 to be statistically significant. RESULTS: One hundred and five patients were treated by CABG/OPCAB (39 female, 66 males). The mean age was 65.7 ±7.3, HbA1c: 7.23 ±1.2%, fructosamine: 261.8 ±43.8. There was no difference in the incidence of other postoperative complications between the two groups. CONCLUSIONS: Glycated hemoglobin and fructosamine levels to a similar extent define the risk of perioperative complications in patients undergoing cardiac surgery. In patients in whom there is a need to quickly compensate for elevated blood glucose consider enabling determination of fructosamine.

Coronary artery disease in heart transplant recipients - diagnosis and treatment. Single centre experience based on results of elective coronary angiography.

BACKGROUND: Despite recent progress in clinical transplantology, coronary artery disease of transplanted heart (TxCAD) remains the main cause of long-term mortality. The role of elective coronary angiography (CAG) and percutaneous coronary interventions (PCI) in these patients has not yet been well established. AIM: To evaluate the incidence of TxCAD based on the results of elective CAG and to assess the role of potential risk factors and treatment options. METHODS: We analysed the results of 227 elective CAG procedures performed in 145 patients after orthotopic heart transplantation (OHT) between 1986 and 1998. The result of CAG was considered positive when any lesion was found in coronary arteries regardless of its hemodynamic relevance, including both atherosclerotic plaques and lesions characteristic of vasculopathy. The influence of immunological (rejection of transplanted heart) and non-immunological risk factors on the development of TxCAD was analysed separately for the first 3 years after OHT and for the subsequent period. RESULTS: Positive result of at least one CAG was found in 54 (37%) patients. The overall percentage of positive CAG was 41%, starting from 18% one year after OHT to 55% five years after surgery. Vasculopathic lesions were found in 14% of CAG procedures. Risk factor analysis showed an increasing impact over time of non-immunological factors, however, differences were not statistically significant. Hemodynamically significant lesions were found in 21 patients. In 16 of those PCI was performed. Control CAG was done in 12 patients after PCI revealing indications for another PCI in 8 of them. TxCAD was the cause of death in 3 patients in the PCI group. CONCLUSIONS: Based on the results of elective CAG, frequency of TxCAD increases with time and reaches 55% by 5 years after OHT. PCI is an effective method of treating significant coronary lesions after OHT.

Influence of long term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation.

Diabetes mellitus is a very well recognized risk factor for coronary artery disease in non-transplant patients. With the introduction of new immunosuppressive agents in solid organ recipients, there is an interest in medical complications of immunosuppressive therapy. An influence of long-term cyclosporine-A (CyA) therapy on glucose metabolism was analyzed in a group of 122 heart transplant recipients who developed hyperglycemia after heart transplantation. Based on WHO criteria for diagnosis of diabetes two groups were identified: group 1 (102 pts) included pts with impaired glycemic control and group 2 (20 pts) with clinical diabetes. Fasting insulin, proinsulin, C-peptide, HbA1c and cyclosporine-A trough levels were determined 12-18 months post surgery in clinically stable period without transplant rejection. The immunosuppressive treatment in both groups was the same and consisted of cyclosporine A, azathioprine and prednisone. We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups.

Diagnosis and treatment of steroid resistant cellular rejection in heart transplant recipients--single center experience.

OBJECTIVES: Aim of the study was to assess frequency and risk factors of steroid resistant cellular rejection (SRR) in heart transplant recipients, to determine methods of its treatment, and to evaluate influence of steroid resistant rejection and method of its treatment on short- and long-term results. METHODS: All pts. received cyclosporine-A, azathioprine and prednisone. Biopsy results > or = 3A (ISHLT) were considered a significant rejection, requiring treatment with 1 g i.v. methylprednizolone for 3 days followed by oral prednisone. SRR was recognized in case of biopsy-proven progression of rejection, lack of improvement in 2 consecutive biopsies, or increasing hemodynamic compromise despite treatment of biopsy-proven rejection. 146 pts. eligible for the study were divided into: study group--15 pts. with SRR (10%), and control group--131 pts. SRR was treated with: cytolytic therapy--ATG (10 pts.), mycophenolate mofetil (3 pts.) or steroids (2 pts.). Number of biopsies > or = 3A, cumulative biopsy score, average biopsy result, effectiveness of SRR treatment, side effects of therapy, and survival were analysed. RESULTS: All parameters characterizing rejection were significantly higher in the study group. No risk factors of SRR were found. In 6 pts. with SRR and hemodynamic compromise (all treated with ATG) improvement was observed in 4 pts, while death occurred in 2 pts. There were no deaths in pts. without hemodynamic compromise--none of 3 methods of treatment was superior, however ATG increased the infection risk. Survival in the 1st year was significantly lower in the study group (67% vs. 89% in the control group). CONCLUSIONS: SRR is recognized in about 10% of heart transplant recipients, increasing risk of death in the 1st year after surgery. Cytolytic therapy increases risk of infection, and should be avoided in pts. without hemodynamic compromise.

Atrial pacing of transplanted heart.

UNLABELLED: Orthotopic heart transplantation (OHT) is most effective method for treatment of irreversible heart failure. Patients after OHT considered for permanent pacing consist still present a challenge for the implanting physician due to distorted atrial geometry and specific electrophysiological conditions of atrium. The aim of our study was to analyse the effectiveness of permanent atrial pacing in these patients. PATIENTS AND METHODS: We implanted atrial lead in 37 SND pts., 2 months--7 years after OHT, (3 pts with coexisting AV block received ventricular lead). Only straight BP screw-in leads and manually formed stylets were used; we found satisfactory pacing/sensing conditions in 25 pts in RA appendage or anterior/lateral wall, in 10 pts--in CS ostium region and in 2--in proximal part of CS. RESULTS: All implantations were successful and no patient received VVI pacing system. One dislodged lead required revision (1/37, 3%) but this was not related to endomyocardial biopsy. In 2 pts, due to unacceptable low RA potential and/or high PTh values atrial lead was implanted to CS for sensing/pacing of left atrium. The average acute value of A wave were 2.4 mV and chronic 2.2 mV; values of pacing threshold were 0.9 V and 1.6 V respectively. Only in 13/37 pts native A waves were recorded but with amplitude < 0.6 mV. Wenckebach point was 120/min only in 2 pts., in borders 130-160 bpm in 15 pts. and exceeded 170 bpm. in remained 20 pts. Retrograde VA conduction was intact in 33/37 pts, but in 4 pts exceeded 260/min. During long term follow-up in no patient we observed AV conduction disturbances. In 6 pts. treadmill exercise (Bruce's protocol) was repeated three times during: sinus (spontaneous) rhythm, AAI pacing 70/min, AAI-R (DDD-R) pacing. AAI 70 bpm did not influence significantly attained workload, heart rate on peak exercise or duration of exercise. But atrial rate modulated pacing increased values of examined parameters significantly. CONCLUSIONS: 1. Atrial pacing (and atrial based pacing modes) are possible in majority of transplanted heart patients. 2. Frequency of atrial lead dislocation, appearance of atrial sensing problems and AV conduction disturbances (all in about 3%) are comparable to non-transplanted patients. 3. In most patients with SND after OHT AV conduction remains within normal limits; it indicates safety of rate responsive pacing modes in these patients. 4. Rate modulated atrial pacing improves exercise tolerance in heart transplanted patients with SND. 5. High ("supra-normal") values of Wenckebach's point observed in most of patients with transplanted (dennervated) heart may have clinical importance in cases of atrial arrhythmias in these patients.